23andMe and Genentech to analyze genomic data for Parkinson's disease

09-Jan-2015 - USA

23andMe, Inc. announced an agreement with Genentech to generate whole genome sequencing data for approximately 3,000 people in 23andMe's Parkinson's disease community. The goal of the collaboration is to identify new therapeutic targets for treating Parkinson's disease.

This multi-year collaboration provides Genentech with the ability to identify potential therapeutics based on genome sequencing and survey data from the largest Parkinson's disease community of its kind. Following the conclusion of the collaboration, 23andMe will have the ability to conduct additional research on the data, as well as the ability to make the information available to Parkinson's researchers from around the world. Consistent with 23andMe's commitment to the privacy of research participants, de-identified individual-level data will only be shared from those individuals who provide explicit permission to 23andMe to do so.

Other news from the department business & finance

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics